Device for dispensing intraocular substances

- Novartis AG

This disclosure relates generally to an injection device having a plunger configured to advance a distance into a container of material, such as a viscoelastic container; a trigger mechanism configured upon an actuation of the trigger mechanism to apply a first force to a spring element; and the spring element coupled to the plunger and configured to apply a second force to the plunger and which is configured to prevent exceeding a threshold maximum force applied to the container.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Patent Application Ser. No. 61/812,606, titled “Device for Dispensing Intraocular Substances,” filed Apr. 16, 2013, the disclosure of which is hereby incorporated by reference in its entirety herein. Priority of the aforementioned filing date is claimed.

BACKGROUND

During ophthalmic surgeries, fluids are injected into the eye for various purposes. Viscoelastic substances may be injected into the eye to open the anterior chamber and allow working room for the surgeon within the chamber. Viscoelastic substances may also be injected into other structures to allow the structures to remain patent post-operatively. For example, viscoelastic may be injected into the Schlemm's Canal in a procedure called a ‘viscocanalostomy’ or a ‘canaloplasty’. Viscoelastic may also be injected into the suprachoroidal space to maintain a cleft. These procedures may be done in conjunction with an implant or as a separate procedure.

SUMMARY

Disclosed herein are devices, systems and methods for intraocular delivery of materials from a container.

In one aspect, disclosed is an injection device having a housing configured to reversibly couple to a container holding a material; a plunger moveably coupled to a piston and configured to move a distance into the container; a spring element; and a trigger mechanism coupled to the housing and configured to move the plunger the distance.

The device can further include an adjustment mechanism slideably positioned within the housing. The spring element can be coupled to the adjustment mechanism. The trigger mechanism can be configured to actuate the adjustment mechanism to apply a force to move the plunger the distance. The plunger can move axially along a given length within the piston. The plunger can include a proximal end region and a distal end region. The proximal end region of the plunger can include an elongate slot. The piston can include a distal opening to a bore through which the proximal end region of the plunger is configured to insert. The piston can include sidewalls having a pair of openings configured to align with the elongate slot of the plunger. The spring element can be positioned within the bore of the piston between the proximal end region of the plunger and a distal end of the bore. The spring element can be configured to apply a spring force counter to the force applied to move the plunger the distance preventing the force to move the plunger from exceeding a threshold maximum force. The spring element can press on the proximal end region of the plunger and causes the plunger to move distally. The spring element can compress between the proximal end region of the plunger and the distal end of the piston bore when a force within the container is above the force of the spring element. The trigger mechanism can prevent the adjustment mechanism from moving in a rearward proximal direction and allows free movement of the adjustment mechanism in a forward distal direction. The trigger mechanism can include a rotating handle and a pivoting latch constrained by the rotating handle. The piston can include a lower surface having a plurality of notches. The pivoting latch can be configured to engage with one notch of the plurality of notches on the lower surface of the piston. The rotating handle can rotate relative to the housing towards a piston grip handle. The pivoting latch can push against the one notch when the rotating handle rotates moving the adjustment mechanism the distance. The housing can include an upper surface having a slot through which the container is loaded. The container can include a barrel, a stopper slideably disposed within the barrel, and an outlet. The outlet can remain external to the housing when the container is loaded in the slot. The plunger can have a distal end that reversibly engages a proximal end of the stopper. The stopper can include a notch in the proximal end and the plunger can include a projection from the distal end. The projection and notch can have corresponding shapes. The container can contain a viscoelastic material. A metered volume of the material can be delivered from the container with each actuation of the trigger mechanism. The metered volume can depend upon the distance and a cross-sectional area of the container.

In an interrelated aspect, disclosed is an injection device including a plunger configured to advance a distance into a container holding a material; a pushing mechanism configured upon movement of the pushing mechanism to apply a force to a spring element; and the spring element configured to apply the force to the plunger and which is configured to dampen the distance moved by the pushing mechanism from the distance moved by the plunger.

A user may impart a force on the pushing mechanism and therein cause the pushing mechanism to move a predetermined distance toward the plunger. The spring element can exist between the plunger and the pushing mechanism such that the pushing mechanism contacts the spring element which in turn contacts the plunger. As the pushing mechanism advances forward it applies a force onto the spring element which in turn applies the force on the plunger.

The plunger in turn applies the force on a moveable stopper within the container of the material such that the pressure of the material within the container increases. The material may then exit through an outlet of the container. The outlet of the container can be connected to a small delivery lumen tubing which can require high pressure for the material to flow, particularly viscous materials.

The spring element can be, for example, a compression spring that is axially constrained with a given threshold force. When the force applied by the pushing mechanism is less than the spring threshold force, the spring does not compress further and the distance traveled by the pushing mechanism is the same over time as the distance traveled by the plunger. However, if the force necessary by the plunger to expel the material from the container is higher than the threshold force, the spring element compresses and the distance traveled by the pushing mechanism may not be the same as the distance traveled by the plunger over time. For example, the pushing mechanism may move a distance of 0.030″ in 2 seconds, while the plunger may move the same distance of 0.030″ but in a time of 5 seconds. In this example, the material exits the outlet of the container over a longer period of time at a slower rate and therefore the peak pressure reached in the container may be less than if no spring element was present.

In an embodiment, he plunger can move axially along a given length within a piston. The plunger can include a proximal end region and a distal end region. The proximal end region of the plunger can include an elongate slot. The piston can include a distal opening to a bore through which the proximal end region of the plunger is configured to insert. The piston can include sidewalls having a pair of openings configured to align with the elongate slot of the plunger. The spring element coupled to the plunger can be positioned within the bore of the piston between the proximal end region of the plunger and a distal end of the bore. The spring element can press on the proximal end region of the plunger and cause the plunger to move distally. The spring element can compress between the proximal end region of the plunger and the distal end of the piston bore when a force within the container is greater than the second force of the spring element. The trigger mechanism can include a rotating handle and a pivoting latch constrained by the rotating handle. The piston can include a lower surface having a plurality of notches. The pivoting latch can be configured to engage with one notch of the plurality of notches on the lower surface of the piston. The rotating handle can rotate relative to the housing towards a piston grip handle. The pivoting latch can push against the one notch when the rotating handle rotates moving the adjustment mechanism the distance. The housing can include an upper surface having a slot through which the container is loaded. The container can include a barrel, a stopper slideably disposed within the barrel, and an outlet. The outlet can remain external to the housing when the container is loaded in the slot. The plunger can have a distal end that reversibly engages a proximal end of the stopper. The stopper can include a notch in the proximal end and the plunger can include a projection from the distal end. The projection and notch can have corresponding shapes. The container can contain a viscoelastic material. A metered volume of the material can be delivered from the container with each actuation of the trigger mechanism. The metered volume can depend upon the distance and a cross-sectional area of the container.

More details of the devices, systems and methods are set forth in the accompanying drawings and the description below. Other features and advantages will be apparent from the description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other aspects will now be described in detail with reference to the following drawings. Generally speaking the figures are not to scale in absolute terms or comparatively but are intended to be illustrative. Also, relative placement of features and elements may be modified for the purpose of illustrative clarity

FIG. 1A shows an isometric view of an implementation of an injection device and a container;

FIG. 1B shows an exploded view of the injection device of FIG. 1A;

FIG. 2 shows an isometric view of the injection device of FIG. 1A having the container loaded;

FIG. 3 shows a side view of the injection device and the loaded container of FIG. 2;

FIG. 4 shows a cross-section of the injection device and the loaded container of FIG. 3;

FIG. 5 shows a cross-section of the injection device and the loaded container of FIG. 3 in a different delivery state;

FIG. 6 shows a detailed cross-section of the injection device and the loaded container of FIG. 3.

FIG. 7 shows a cross-section of another implementation of an injection device having a container loaded therein;

FIGS. 8, 9, and 10 show isolated side views of an implementation of a trigger mechanism.

 DETAILED DESCRIPTION

This disclosure relates generally to methods and devices for dispensing intraocular substances. In particular, described are methods and devices for dispensing metered doses of a material, such as viscoelastic substances, into an eye at metered doses within a given force range or below a given force limit. U.S. patent application Ser. No. 11/615,810 filed Dec. 22, 2006 and entitled GLAUCOMA TREATMENT DEVICE is incorporated herein by reference in its entirety.

Viscoelastic substances generally can be supplied in prepackaged containers. The containers can include a syringe and plunger where a user can manually press the plunger on the syringe vial to dispense the viscoelastic through a distal outlet. Manually pressing the plunger can be difficult to control and can result in inaccuracies in the measured amount of material dispensed from the syringe vial. The syringe vial can have gradations and markings to aid the user for measuring the amount of material dispensed. These markings can still be problematic when it is desired to deliver small quantities. Further, intraocular delivery of material to very small structures such as in the eye can require instrumentation having very small lumen size. The force required to inject material through these small lumens is relatively high and can be difficult for a user to manually depress the syringe plunger. Additionally, injection of materials at high pressures may not be desirable, since exemplary tissue structures can be delicate and high pressure or velocity injection can damage the structures. Other injection devices may exist which provide metered dosing of material and offer a mechanical advantage to the user such that the activation force is reduced. However, these can allow the user to inject materials at higher pressures and velocities than may be desirable. An injection device which includes metered dosing and which limits the pressure and velocity of the injected materials would be useful.

Although the injection devices herein are described in the context of injecting viscoelastic material from a container into the eye, it should be appreciated that the injection device can be useful for the injection of a variety of materials or drugs to a variety of locations within a patient. For example, precise volumes of a balanced saline solution (BSS) can be injected into the eye during a variety of ophthalmic procedures. Additionally, precise amounts of drug can be injected into the eye or other locations during surgical procedures or for therapeutic treatments, for example, alcohol ablation of cardiac tissue in which metered dose of alcohol are desired.

FIGS. 1A-1B illustrate an implementation of an injection device 100 that can be used to deliver material from a container 10. The injection device 100 can include an adjustment or pushing mechanism 110, a housing 115, and a spring element. FIG. 1A shows the injection device 100 having a container 10 about to be loaded and FIGS. 2 and 3 show the injection device 100 with the container 10 loaded into the housing 115.

The container 10 can be a syringe-type container having a distal end region 30, a proximal end region 70 and a barrel 60 within which liquid material can be contained and through which a stopper 20 (see FIGS. 4, 5, and 6) can slide to expel the material from the barrel 60 through a distal outlet 40 in the distal end region 30 of the container 10. The distal outlet 40 can have a needle 50 attached (see FIG. 1A). The proximal end region 70 of the container 105 can include a flange 90. The container 10 can be a viscoelastic container having a variety of container types including any commercially-available viscoelastic product used for ophthalmic surgeries such as HEALON 5 (AMO), HEALON GV (AMO), PROVISC (Alcon), or the like, which are typically sold in a syringe vial used for the injection of the material.

Additionally other materials may be commixed for delivery. For example, the viscoelastic substance may be mixed with pharmaceutical agents such as antiproliferative drugs, steroids, or any other drug. In this embodiment, the drug mixed with the viscoelastic material may release over a longer period of time than if the drug was injected without mixing it with the viscoelastic.

Again with respect to FIG. 1A, the housing 115 of the injection device 100 can include a bore 125 that can extend from near a distal end 130 of the housing 115 towards a proximal end 135 of the housing 115. The housing 115 can accept at least a portion of the container 10 within a slot 147 near a distal end 130 of the housing 115 that can align with the bore 125. The slot 147 can be available from an upper surface 140 of the housing 115 such that the container 10 can be loaded in a top-down direction into the housing 115. In this implementation, the slot 147 can include a grooved fitting 145 through which the flange 90 of the proximal end region 70 of the container 10 can be inserted such that the barrel 60 is co-axially aligned with a longitudinal axis A of the bore 125. In an alternative embodiment, the slot 147 can be available from another surface such as a side surface or the bottom surface. Additionally, a latching mechanism can be used that has an open and closed state to allow the container 10 to be inserted into the slot 147 and then prevented from coming out when the latching mechanism is in a closed state. The distal outlet 40 of the distal end region 30 of the container 10 (and needle 50, if present) can remain external to the distal end 130 of the housing 115 such that it is available for tissue injection.

As mentioned above, the injection device 100 can include a pushing mechanism 110 to dispense material from within a container 10 slideably positioned within the bore 125 of the housing 115. As best shown in FIG. 1B and FIG. 4, the pushing mechanism 110 can include a plunger 405, an advancing block 410, and an adjustment element, such as an adjustment rod 415 that extends co-axially aligned with the longitudinal axis A through the housing 115 along at least a portion of the bore 125. The plunger 405 can be positioned within the bore 125 extending distal to the advancing block 410, which can extend distal to the adjustment rod 415, which can extend out the proximal end 135 of the housing 115. As will be described in more detail below, the plunger 405 can extend out of the bore 125 into the slot 147 of the housing in order to insert through a proximal end region of the container 10 to interface with the stopper 20 slideably disposed within the barrel 60 of the container 10 to dispense material out the distal outlet 40.

Still with respect to FIG. 1B and FIG. 4, the adjustment rod 415 can be an elongate element having a distal end region and a proximal end region. The adjustment rod 415 can extend co-axially along the longitudinal axis A of the bore 125. The distal end region of the rod 415 can insert through the proximal end 135 of the housing 115 into bore 125. The distal end region of the rod 415 can include threaded feature(s) that engage with the bore 125 allowing the rod 415 to be screwed into and out of the bore 125 as the rod 415 is turned. There, the distal end region of the adjustment rod 415 can insert through and couple with a proximal end region of the adjustment block 410 via washer element 442. The proximal end region of the rod 415 can remain external to the housing 115 and available to a user from outside the housing 115. The proximal end region of the rod 415 can include a knob 440 that can be rotated by the user to advance the adjustment rod 415 in a distal direction. Rotation of the knob 440 by a user can result in the adjustment rod 415 moving distally relative to the adjustment block 410.

It should be appreciated that the injection device need not include an adjustment rod 415 extending co-axially with longitudinal axis A within the bore 125 of the housing 115. As shown in FIG. 7, the injection device can include an adjustment element that includes a sliding actuator 705 attached to a surface of the advancing block 410, such as an upper surface, such that the sliding actuator 705 extends along an axis that is orthogonal to the longitudinal axis A. The sliding actuator 705 can be accessible to a user via an elongate channel in the upper surface 140 of the housing 115. The sliding actuator 705 can be used to manually withdraw the plunger 405 from the proximal end region 70 of the container 10 or manually engage the plunger 405 with the proximal end region 70 of the container 10.

Again with respect to FIG. 1B and FIG. 4, the advancing block 410 can be an element extending along the longitudinal axis A of and within the bore 125. The advancing block 410 can include a distal opening 418 to a bore 420. The opening 418 and bore 420 can be configured to couple with a proximal end region 407 of the plunger 405. The sidewalls of the advancing block 410 can include a pair of openings 422 aligned opposite one another across the bore 420 and configured to align with a slot 425 through the proximal end region 407 of the plunger 405 as will be described in more detail below. A lower surface 427 of the advancing block 410 can have a series of notches 428 (best shown in FIGS. 8, 9, and 10). The proximal end region of the advancing block 410 can include an opening 429 into the bore 420 through which the distal end of the adjustment rod 415 can be inserted to connect with washer element 442 positioned within the bore 420, as described above. An advancing block spring 435 can be positioned within the bore 420 of the advancing block 410 between the proximal end region 407 of the plunger 405 and the distal end region of the bore 420 against the adjustment rod 415.

Still with respect to FIG. 1B and FIG. 4, the plunger 405 can be an elongate element extending along the longitudinal axis A of and within the bore 125. The plunger 405 can have a distal end region 401 and a proximal end region 407. As described above, the proximal end region 407 of the plunger 405 can be configured to insert through the distal opening 418 in the advancing block 410 into bore 420. The outer surface of the proximal end region 407 of the plunger 405 can have a shape that corresponds to the shape of the bore 420, which can be cylindrical or another suitable geometry. The proximal end region 407 of the plunger 405 can have a slot 425 extending through the proximal end region 407 that is configured to align with the pair of openings 422 in the sidewalls of the advancing block 410. The slot 425 and openings 422 can receive a dowel pin 430 therethrough. This arrangement can allow for the plunger 405 to move axially along a given length within the bore 420 of the advancing block 410 before the dowel pin 430 bottoms out against the proximal end of the slot 425. It should be appreciated that the elongate slot need not extend through the entire proximal end region. Rather, the proximal end region 407 also can have a pair of elongate channels configured to align with the pair of openings 422 that in turn, receive a pair of pins 430.

The plunger 405, advancing block 410 and adjustment rod 415 can be retracted towards the proximal end 135 of the housing 115 to allow a container 10 to be inserted within the slot 147 (see FIG. 2). Upon loading a container 10 into the slot 147, the plunger 405 can be advanced distally by actuation of the adjustment mechanism 110 out of the bore 125 the proximal end region of the container 10 positioned within the slot 147 to contact the stopper 20 (see FIG. 5).

FIG. 6 illustrates a detailed view of the plunger 405 pressing against the stopper 20 within the container 10. The distal end region 401 of the plunger 405 can extend into a proximal end of the container 10 to contact and engage the proximal side of the stopper 20. In one implementation, the distal end region 401 of the plunger 405 can have a projection that reversibly engages with a notch 12 located in a proximal side of the stopper 20. The notch 12 can have a shape corresponding to the shape of the projection. The plunger 405 can be urged distally such that it pushes against the stopper 20 and slides the stopper 20 through the barrel 60 towards the distal outlet 40. One or more sealing elements 411, such as O-rings or quad-rings, can be positioned around a portion of the plunger 405 to seal the components of the adjustment mechanism 110 from the material within the container 10 as well as a portion of the adjustment rod.

The injection device 100 also can include a trigger mechanism 120. As shown in FIGS. 4, 5, 8, 9, and 10 the trigger mechanism 120 can include a trigger handle 605, a front latch 615, a rear latch 620, and a release button 630 (shown in FIG. 1A). The front latch 615 can have a pivot point 615p constrained by the housing 115. The front latch 615 can also include an extension 617 that can sit within a notch 428 of the ribbed lower surface 427 of the advancing block 410. The rear latch 620 can have a pivot point 620p constrained by the rotating trigger handle 605 and an extension 627 that can sit within another notch 428 of the ribbed lower surface 427 of the advancing block 410. The front latch 615 and rear latch 620 can include torsion springs 624, 625 to urge the respective extensions 617, 627 into their respective notches 428 of the ribbed lower surface 427 of the advancing block 410. This can constrain the advancing block 410 from moving in a rearward or proximal direction while allowing for free movement of the advancing block 410 in a forward or distal direction.

The trigger handle 605 can be squeezed by a user such that it rotates relative to the housing 115 such as towards a pistol grip handle 117. It should be appreciated that the housing 115 can take on a variety of hand-held shapes and need not include a pistol grip handle 117. For example, the housing 115 can be configured to include a squeeze grip having the trigger mechanism 120 extending at an acute angle along the axis length of the housing 115. Any other number of configurations and designs can be used to orient the trigger mechanism 120 ergonomically or functionally along the housing 115.

As the trigger handle 605 rotates (arrow R in FIG. 9), the rear latch 620 can push against a notch 428 of the lower surface 427 of the advancing block 410 urging the advancing block 410 forward in the direction of arrow D along distance d. The pivot distances of the trigger handle 605 and the rear latch 620 provide a mechanical advantage that can allow a user to impart small forces at the trigger handle 605 that are translated into larger forces along the advancing block 410.

As the advancing block 410 advances distally along arrow D, the advancing block 410 applies a force to the proximal end of the advancing block spring 435 positioned within the bore 420 of the advancing block 410. The distal end of the advancing block spring 435, in turn, can press on the proximal end of the plunger 405 and cause it to move distally, such as further into the barrel 60 of the container 10 onto the stopper 20. The advancing block spring 435 can be, for example, a compressive spring element such as a compression spring as shown in the figures. The advancing block spring 435 can be constrained within the advancing block 410 such that it is maintained with an axial compressive load of a set threshold force. For example, the threshold force of the advancing block spring 435 can be between 5 and 75 lbf. In an exemplary embodiment, the threshold force can be 25 lbf. When the user activates the trigger handle 605 causing the advancing block 410 to move forward, a force is applied to the advancing block spring 435. The advancing block spring 435 in turn applies the force to the plunger 405. As the plunger 405 applies a force to the stopper of the container 10, the pressure of the material within the container 10 increases causing material to exit from the distal outlet 40. If the force required by the plunger 405 to cause the material to exit the outlet is less than the threshold force of the advancing spring block 435, then the advancing block spring 435 may not compress further and the movement of the advancing block 410 will be directly and linearly connected to the movement of the plunger 405 and therefore the rate of flow of the material through the distal outlet 40. This may be the case for materials that have a lower viscosity or if the container 10 is connected to a delivery instrument with a larger delivery lumen. However, if the force required by the plunger 405 to cause material to exit the distal outlet 40 is higher than the threshold force of the advancing block spring 435, then the advancing block spring element 435 may compress further. For example, if the threshold force is set a 25 lbf and the force required for material to flow through the distal outlet 40 of the container 10 at the rate of movement by the advancing block 410 reaches a peak force of 30 lbf, then the advancing block spring 435 may compress. The final distance moved by the advancing block 410 and the plunger 405 may be the same, but the time of the movement may be longer or the plunger 405. Therefore the flow rate of the material at the outlet and the peak pressure in the container 10 may be reduced.

As such, the user can be prevented from inducing a pressure on the container 10 that is higher than the force of the advancing block spring 435. This can be useful because pressures in the container 10 or applied to any component connected to the container 10 above a certain maximum force can cause a failure of those assemblies, which can be of particular importance when the mechanical advantage of a trigger mechanism 120 is so great that the user may not realize the excessive force is being applied. Additionally, the pressure and velocity of the material exiting the device in a tissue structure can be reduced. Therefore, the risk of damage to the tissue caused by pressures and velocities which are excessive can be potentially reduced.

In an alternative and interrelated implementation, the advancing block spring 435 can be a preloaded spring that has sufficient force to advance the plunger 405 distally. Instead of the trigger mechanism 120 exerting a force on the plunger 405 to push the plunger 405 forward as described above, the trigger mechanism 120 can meter the amount the plunger 405 is advanced by the preloaded advancing block spring 435.

Now with respect to FIG. 10, once the trigger handle 605 is released by the user, a torsion spring 610 within the trigger handle 605 can return the trigger handle 605 to its start position and the front latch 615 can engage with the next notch 428 in the lower surface 427 of the advancing block 410. The advancing block spring 435 can return to its extended state. The front latch 615 can hold the mechanism stationary while the trigger handle 605 and rear latch 620 return to the start position allowing for step-wise advancement with trigger actuation. The user can repeat the process and squeeze the trigger handle 605 again to dispense another aliquot of material from the container 10. Each time the trigger handle 605 is squeezed, the advancing block 410 and plunger 405 can advance the distance d.

The metered volume of material delivered from a container 10 with each trigger handle 605 actuation can depend upon the travel distance d and the cross-sectional area of the container 10. Additionally, the travel distance d can vary along the axial length of the advancing block 410. The travel distance d can be the size of one advancing block notch 428 of the lower surface 427. In some implementations, the distance d can be between approximately 0.020″ to approximately 0.060″. In other implementations, the distance d can be 0.005″ to approximately 0.120″. The cross-sectional area of the container 10 can vary. The container 10 can have a cross-sectional area of 0.010 square inches to approximately 0.400 square inches.

For some containers, such as Healon 5, a distance d of approximately 0.036″ of travel can correspond to approximately 60 uL of material dispensed from the container having cross-sectional area of approximately 0.050 square inches. It can be desirable to have an injector device 100 having alternate travel distances d depending on the cross-sectional area of the container intended to be used with the injector device 100. Other amounts or containers having other cross-sectional areas may have alternate distances d of the advancing block notches. For example, a first injection device 100 having a first distance d can be useful for the delivery of material from a first container having a first cross-sectional area according to a first metered dose of material. A second injection device 100 may have a second, larger distance d and can be useful for the delivery of material from a second container having a second, smaller cross-sectional area to deliver that same metered dose of material. In general, the equation V=A*d can be used to relate the distance d, the cross-sectional area A, and the volume displaced V.

The user can repeat the process and squeeze the trigger handle 605 again and again. Each time the trigger handle 605 is squeezed, the plunger 405 can advance the predetermined distance d. The lower surface 427 of the advancing block 410 can include notches 428 up to a predetermined point such that the plunger 405 is prevented from advancing beyond a certain overall distance into the container 10. For example, when the plunger 405 is close to the end of the container 10, it can be desirable for the plunger 405 to move no further in the distal direction.

Once the desired amount of material from the container 10 has been dispensed using the injection device 100, the user can release the container 10 from the injection device 100 by pressing the release button 630. The release button 630 can be located on the housing 115, for example along the side of the housing 115, extending through to pull the front latch 615 and the rear latch 620 away from the lower surface 427 of the advancing block 410 such that the advancing block 410 is clear to return in a rearward or proximal direction. The release button 630 can be connected to a cam shaft that translates the movement of the release button 630, which is perpendicular to the axial movement used to move the front latch 615 and the rear latch 620 away from the lower surface 427 of the advancing block 410, into an axial movement. A pin can be contained within a slot on the release button 630 and also contained by a hole on the cam shaft. As the release button 630 slides into the housing 115, the pin can be driven distally by the slot which, in turn, can pull the cam shaft distally and pull down the front latch 615 and the rear latch 620. A spring 418 can be positioned within bore 125 surrounding a portion of plunger 405 just distal to the proximal end region 407 (see FIGS. 5 and 7). The spring 418 can push the plunger 405, advancing block 410 and adjustment rod 415 in a proximal direction until the plunger 405 is withdrawn out from the barrel 60 of the container 10. Once the distal end 401 of the plunger 405 is clear of the container 10, the container 10 can be removed from the injection device 100, such as back up through the upper slot 147 of the fitted groove 145 region. The injection device 100 can be designed to be a single-use disposable device. Alternatively the injection device 100 can be a sterilizable device designed for reuse to deliver material from another container 10.

One or more components of the injection device 100, such as the trigger mechanism 120, can be formed of one or more biomedical compatible materials including, but not limited to biocompatible metals, anodized aluminum, stainless steel, or titanium. Alternatively, one or more components of the injection device 100 such as the trigger mechanism 120 can be formed of plastics such as polycarbonate, nylon, DELRIN or other suitable material. The components can be manufactured through machining processes such as milling or turning. Alternatively components can be manufactured through injection molding techniques or other suitable process. High strength components such as the advancing block 410, the front latch 615 and rear latch 620 can be formed of a metal material. Springs within the device such as the advancing block spring 435 and the spring 418 can be a plastic or metal material, including but not limited to stainless steel, music wire, a series of spring washers or other suitable material for delivering an appropriate force. In other embodiments the advancing block spring 435 or spring 418 can be a series of spring washers or a plastic plug capable of providing a spring force and spring rate. Forces delivered by one or both of the springs 435, 418 can be between about 10 lbf to about 40 lbf. Alternatively, forces delivered by one or both of the springs 435, 418 can be between about 5 lbf to about 75 lbf.

In other embodiments, the pushing mechanism for applying a force to the spring element may be any other variety of mechanisms such as a screw thread mechanism, a hydraulic mechanism, or any other suitable mechanism for advancing at predetermined distances.

While this specification contains many specifics, these should not be construed as limitations on the scope of what is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results. Only a few examples and implementations are disclosed. Variations, modifications and enhancements to the described examples and implementations and other implementations may be made based on what is disclosed.

Claims

1. An ophthalmic injection device, comprising:

a pistol-shaped housing having a grip handle and an elongated slot formed by straight edges formed on and extending through an outer side wall of the housing such that the slot is on an outer surface of the injection device:
a plunger mechanically coupled to the housing and configured to advance a distance into a container holding a material;
a pushing mechanism coupled to the housing and configured, upon an actuation of the pushing mechanism of a distance, to apply a force to a spring element, wherein the pushing mechanism comprises a trigger handle that pivots toward the grip handle when actuated; and
the spring element contained entirely within the housing and configured to apply the force to the plunger and configured to dampen the distance moved by the pushing mechanism from the distance moved by the plunger; and the container,
wherein the container is a cylindrical body that fits into the slot of the housing, wherein the container inserts into the slot on the outer side wall of the housing and wherein the container has a blunt distal end; and
a small delivery lumen configured to communicate with the container, wherein the small delivery lumen has an outlet configured to be placed within a structure of an eye.

2. The device in claim 1, wherein the spring element prevents the force applied to the plunger from reaching a threshold maximum.

3. The device in claim 1, wherein a metered volume of the material is delivered from the container with each actuation of the pushing mechanism.

4. The device in claim 3, wherein the metered volume is between 5 uL and 100 uL.

5. The device in claim 1, wherein the spring element is a compressive spring element.

6. The device in claim 5, wherein the compressive spring element is a compression spring.

7. The device in claim 5, wherein the compressive spring element has a spring rate of 30 lb/in to 150 lb/in.

8. The device in claim 5, wherein the compressive spring element is constrained axially in a state of compression such that the initial force to further compress the compressive spring element is a predetermined force.

9. The device in claim 8, wherein the initial force to further compress the compressive spring element is between 2 lbf and 50 lbf.

10. The device in claim 8, wherein the initial force to further compress the compressive spring element is adjustable.

11. The device in claim 1, wherein the container comprises a barrel, a stopper slideably disposed within the barrel, and an outlet.

12. The device in claim 11, wherein the plunger has a distal end that reversibly engages an end of the stopper.

13. The device in claim 12, wherein the plunger advances toward the outlet of the container and is configured to expel the material through the outlet.

14. The device in claim 11, wherein the outlet of the container communicates fluidly with a small delivery lumen.

15. The device in claim 14, wherein the small delivery lumen has an inner cross sectional area between 2.0E-4 in2 and 50E-4 in2.

16. The device in claim 1, wherein the structure of the eye is the suprachoroidal space.

17. The device in claim 1, wherein the structure of the eye is the Schlemm's Canal.

18. The device in claim 1, wherein the material in the container is a viscous substance.

19. The device in claim 18, wherein the viscous substance is a viscoelastic material used during ophthalmologic surgeries.

20. The device in claim 19, wherein the viscoelastic material is mixed with pharmaceutical agents.

21. The device in claim 1, wherein the pushing mechanism includes an advancing block which applies the force to the spring element.

22. The device in claim 21, wherein the pushing mechanism further includes a ratcheting mechanism wherein the advancing block may be moved by a predetermined distance upon activation of the pushing mechanism.

23. The device in claim 22, wherein the ratcheting mechanism includes at least one latch which engages with the advancing block and is configured such that the advancing block may not move in a proximal direction.

24. The device in claim 21, wherein the pushing mechanism includes a trigger which may engage with the advancing block to advance the advancing block by a predetermined distance when actuated.

25. The device in claim 24, wherein the predetermined distance is between 0.010 in and 0.075 in.

26. The device in claim 21, wherein the pushing mechanism includes a screw mechanism wherein the advancing block moves a predetermined distance upon a given rotation of the advancing block.

Referenced Cited
U.S. Patent Documents
3439675 April 1969 Cohen
3767759 October 1973 Wichterle
3788327 January 1974 Donowitz et al.
3915172 October 1975 Wichterle et al.
4037604 July 26, 1977 Newkirk
4402681 September 6, 1983 Haas et al.
4457757 July 3, 1984 Molteno
4521210 June 4, 1985 Wong
4554918 November 26, 1985 White
4604087 August 5, 1986 Joseph
4634418 January 6, 1987 Binder
4722724 February 2, 1988 Schocket
4750901 June 14, 1988 Molteno
4787885 November 29, 1988 Binder
4826478 May 2, 1989 Schocket
4846172 July 11, 1989 Berlin
4863457 September 5, 1989 Lee
4886488 December 12, 1989 White
4900300 February 13, 1990 Lee
4946436 August 7, 1990 Smith
4968296 November 6, 1990 Ritch et al.
5041081 August 20, 1991 Odrich
5071408 December 10, 1991 Ahmed
5073163 December 17, 1991 Lippman
5092837 March 3, 1992 Ritch et al.
5127901 July 7, 1992 Odrich
5171213 December 15, 1992 Price, Jr.
5178604 January 12, 1993 Baerveldt et al.
5180362 January 19, 1993 Worst
5284476 February 8, 1994 Koch
5300020 April 5, 1994 L'Esperance, Jr.
5338291 August 16, 1994 Speckman et al.
5342370 August 30, 1994 Simon et al.
5346464 September 13, 1994 Camras
5370607 December 6, 1994 Memmen
5372577 December 13, 1994 Ungerleider
5397300 March 14, 1995 Baerveldt et al.
5423777 June 13, 1995 Tajiri et al.
5433701 July 18, 1995 Rubinstein
5443505 August 22, 1995 Wong et al.
5454746 October 3, 1995 Guegan et al.
5476445 December 19, 1995 Baerveldt et al.
5558629 September 24, 1996 Baerveldt et al.
5558630 September 24, 1996 Fisher
5571189 November 5, 1996 Kuslich
RE35390 December 3, 1996 Smith
5601094 February 11, 1997 Reiss
5626558 May 6, 1997 Suson
5626559 May 6, 1997 Solomon
5651782 July 29, 1997 Simon et al.
5676944 October 14, 1997 Alvarado et al.
5702414 December 30, 1997 Richter et al.
5704907 January 6, 1998 Nordquist et al.
5713844 February 3, 1998 Peyman
5741292 April 21, 1998 Mendius
5743868 April 28, 1998 Brown et al.
5749879 May 12, 1998 Middleman et al.
5752928 May 19, 1998 de Roulhac et al.
5807244 September 15, 1998 Barot
5807302 September 15, 1998 Wandel
5868697 February 9, 1999 Richter et al.
5882327 March 16, 1999 Jacob
5893837 April 13, 1999 Eagles et al.
5941250 August 24, 1999 Aramant et al.
5968058 October 19, 1999 Richter et al.
6007510 December 28, 1999 Nigam
6007511 December 28, 1999 Prywes
6019786 February 1, 2000 Thompson
6036678 March 14, 2000 Giungo
6050970 April 18, 2000 Baerveldt
6050999 April 18, 2000 Paraschac et al.
6077299 June 20, 2000 Adelberg et al.
6102045 August 15, 2000 Nordquist et al.
6142969 November 7, 2000 Nigam
6186974 February 13, 2001 Allan et al.
6203513 March 20, 2001 Yaron et al.
6221078 April 24, 2001 Bylsma
6251090 June 26, 2001 Avery et al.
6261256 July 17, 2001 Ahmed
6264668 July 24, 2001 Prywes
6331313 December 18, 2001 Wong et al.
6375642 April 23, 2002 Grieshaber et al.
6383219 May 7, 2002 Telandro et al.
6450984 September 17, 2002 Lynch et al.
6464724 October 15, 2002 Lynch et al.
6468283 October 22, 2002 Richter et al.
6471666 October 29, 2002 Odrich
6471777 October 29, 2002 Kobayashi et al.
6494857 December 17, 2002 Neuhann
6508779 January 21, 2003 Suson
6510600 January 28, 2003 Yaron et al.
6524275 February 25, 2003 Lynch et al.
6533768 March 18, 2003 Hill
6537568 March 25, 2003 Olejnik et al.
6544208 April 8, 2003 Ethier et al.
6544249 April 8, 2003 Yu et al.
6558342 May 6, 2003 Yaron et al.
6561974 May 13, 2003 Grieshaber et al.
6579256 June 17, 2003 Hughes
6589203 July 8, 2003 Mitrev
6595945 July 22, 2003 Brown
6626858 September 30, 2003 Lynch et al.
6638239 October 28, 2003 Bergheim et al.
6648283 November 18, 2003 Chase et al.
6666841 December 23, 2003 Gharib et al.
6676607 January 13, 2004 de Juan, Jr. et al.
6699210 March 2, 2004 Williams et al.
6699211 March 2, 2004 Savage
6719750 April 13, 2004 Varner et al.
6726664 April 27, 2004 Yaron et al.
6726676 April 27, 2004 Stegmann et al.
6730056 May 4, 2004 Ghaem et al.
6736791 May 18, 2004 Tu et al.
6741666 May 25, 2004 Henry et al.
6780164 August 24, 2004 Bergheim et al.
6783544 August 31, 2004 Lynch et al.
6827699 December 7, 2004 Lynch et al.
6827700 December 7, 2004 Lynch et al.
6881197 April 19, 2005 Nigam
6881198 April 19, 2005 Brown
6939298 September 6, 2005 Brown et al.
6955656 October 18, 2005 Bergheim et al.
6962573 November 8, 2005 Wilcox
6966888 November 22, 2005 Cullen et al.
6969384 November 29, 2005 de Juan, Jr.
6981958 January 3, 2006 Gharib et al.
6989007 January 24, 2006 Shadduck
7041077 May 9, 2006 Shields
7090681 August 15, 2006 Weber et al.
7094225 August 22, 2006 Tu et al.
7135009 November 14, 2006 Tu et al.
7160264 January 9, 2007 Lisk, Jr. et al.
7163543 January 16, 2007 Smedley et al.
7186232 March 6, 2007 Smedley et al.
7192412 March 20, 2007 Zhou et al.
7195774 March 27, 2007 Carvalho et al.
7207965 April 24, 2007 Simon
7220238 May 22, 2007 Lynch et al.
7273475 September 25, 2007 Tu et al.
7291125 November 6, 2007 Coroneo
7297130 November 20, 2007 Bergheim et al.
7331984 February 19, 2008 Tu et al.
7431710 October 7, 2008 Tu et al.
7488303 February 10, 2009 Haffner et al.
RE40722 June 9, 2009 Chappa
7563241 July 21, 2009 Tu et al.
7708711 May 4, 2010 Tu et al.
7850637 December 14, 2010 Lynch et al.
7857782 December 28, 2010 Tu et al.
7867186 January 11, 2011 Haffner et al.
7867205 January 11, 2011 Bergheim et al.
8075511 December 13, 2011 Tu et al.
8172899 May 8, 2012 Silvestrini et al.
8721656 May 13, 2014 De Juan, Jr. et al.
20010000527 April 26, 2001 Yaron et al.
20010025150 September 27, 2001 de Juan et al.
20020013546 January 31, 2002 Grieshaber et al.
20020013572 January 31, 2002 Berlin
20020026200 February 28, 2002 Savage
20020072673 June 13, 2002 Yamamoto et al.
20020087111 July 4, 2002 Ethier et al.
20020111608 August 15, 2002 Baerveldt et al.
20020128613 September 12, 2002 Nakayama
20020133168 September 19, 2002 Smedley et al.
20020143284 October 3, 2002 Tu et al.
20020156413 October 24, 2002 Williams et al.
20020165478 November 7, 2002 Gharib et al.
20020169130 November 14, 2002 Tu et al.
20020169468 November 14, 2002 Brown
20020177856 November 28, 2002 Richter et al.
20020188308 December 12, 2002 Tu et al.
20020193725 December 19, 2002 Odrich
20030009124 January 9, 2003 Lynch et al.
20030028228 February 6, 2003 Sand
20030055372 March 20, 2003 Lynch et al.
20030060752 March 27, 2003 Bergheim et al.
20030069637 April 10, 2003 Lynch et al.
20030088260 May 8, 2003 Smedley et al.
20030097151 May 22, 2003 Smedley et al.
20030097171 May 22, 2003 Elliott
20030120200 June 26, 2003 Bergheim et al.
20030135149 July 17, 2003 Cullen et al.
20030181848 September 25, 2003 Bergheim et al.
20030187384 October 2, 2003 Bergheim et al.
20030187385 October 2, 2003 Bergheim et al.
20030191428 October 9, 2003 Bergheim et al.
20030208163 November 6, 2003 Yaron et al.
20030220602 November 27, 2003 Lynch et al.
20030220603 November 27, 2003 Lynch et al.
20030229303 December 11, 2003 Haffner et al.
20030232015 December 18, 2003 Brown et al.
20030236483 December 25, 2003 Ren
20030236484 December 25, 2003 Lynch et al.
20040015140 January 22, 2004 Shields
20040024345 February 5, 2004 Gharib et al.
20040050392 March 18, 2004 Tu et al.
20040073156 April 15, 2004 Brown
20040088048 May 6, 2004 Richter et al.
20040092856 May 13, 2004 Dahan
20040097984 May 20, 2004 Zapata
20040102729 May 27, 2004 Haffner et al.
20040111050 June 10, 2004 Smedley et al.
20040127843 July 1, 2004 Tu et al.
20040147870 July 29, 2004 Burns et al.
20040148022 July 29, 2004 Eggleston
20040193095 September 30, 2004 Shadduck
20040193262 September 30, 2004 Shadduck
20040210181 October 21, 2004 Vass et al.
20040210185 October 21, 2004 Tu et al.
20040216749 November 4, 2004 Tu
20040225250 November 11, 2004 Yablonski
20040236343 November 25, 2004 Taylor et al.
20040249333 December 9, 2004 Bergheim et al.
20040254517 December 16, 2004 Quiroz-Mercado et al.
20040254519 December 16, 2004 Tu et al.
20040254520 December 16, 2004 Porteous et al.
20040254521 December 16, 2004 Simon
20040260227 December 23, 2004 Lisk et al.
20040260228 December 23, 2004 Lynch et al.
20050008673 January 13, 2005 Snyder et al.
20050038334 February 17, 2005 Lynch et al.
20050049578 March 3, 2005 Tu et al.
20050090806 April 28, 2005 Lynch et al.
20050090807 April 28, 2005 Lynch et al.
20050101967 May 12, 2005 Weber et al.
20050107734 May 19, 2005 Coroneo
20050119601 June 2, 2005 Lynch et al.
20050119636 June 2, 2005 Haffner et al.
20050119737 June 2, 2005 Bene et al.
20050125003 June 9, 2005 Pinchuk et al.
20050143817 June 30, 2005 Hunter et al.
20050149080 July 7, 2005 Hunter et al.
20050171507 August 4, 2005 Christian et al.
20050175663 August 11, 2005 Hunter et al.
20050181011 August 18, 2005 Hunter et al.
20050181977 August 18, 2005 Hunter et al.
20050182350 August 18, 2005 Nigam
20050191331 September 1, 2005 Hunter et al.
20050192527 September 1, 2005 Gharib et al.
20050197613 September 8, 2005 Sniegowski et al.
20050209549 September 22, 2005 Bergheim et al.
20050209550 September 22, 2005 Bergheim et al.
20050232972 October 20, 2005 Odrich
20050244462 November 3, 2005 Farooq
20050245911 November 3, 2005 Wright et al.
20050250788 November 10, 2005 Tu et al.
20050266047 December 1, 2005 Tu et al.
20050267397 December 1, 2005 Bhalla
20050267398 December 1, 2005 Protopsaltis et al.
20050271704 December 8, 2005 Tu et al.
20050273033 December 8, 2005 Grahn et al.
20050277864 December 15, 2005 Haffner et al.
20050283108 December 22, 2005 Savage
20050288617 December 29, 2005 Yaron et al.
20050288619 December 29, 2005 Gharib et al.
20060004348 January 5, 2006 Scheller et al.
20060020248 January 26, 2006 Prescott
20060032507 February 16, 2006 Tu
20060036207 February 16, 2006 Koonmen et al.
20060047263 March 2, 2006 Tu et al.
20060069340 March 30, 2006 Simon
20060074375 April 6, 2006 Bergheim et al.
20060084907 April 20, 2006 Bergheim et al.
20060116626 June 1, 2006 Smedley et al.
20060149194 July 6, 2006 Conston et al.
20060155238 July 13, 2006 Shields
20060155300 July 13, 2006 Stamper et al.
20060173397 August 3, 2006 Tu et al.
20060195055 August 31, 2006 Bergheim et al.
20060195056 August 31, 2006 Bergheim et al.
20060200113 September 7, 2006 Haffner et al.
20060235367 October 19, 2006 Takashima et al.
20060241580 October 26, 2006 Mittelstein et al.
20060241749 October 26, 2006 Tu et al.
20060276739 December 7, 2006 Brown
20070010827 January 11, 2007 Tu et al.
20070088242 April 19, 2007 Coroneo
20070088424 April 19, 2007 Greenberg et al.
20070088432 April 19, 2007 Solovay et al.
20070106235 May 10, 2007 Coroneo
20070106236 May 10, 2007 Coroneo
20070112292 May 17, 2007 Tu et al.
20070118147 May 24, 2007 Smedley et al.
20070149915 June 28, 2007 Yablonski
20070191863 August 16, 2007 De Juan et al.
20070207186 September 6, 2007 Scanlon et al.
20070233037 October 4, 2007 Gifford et al.
20070276315 November 29, 2007 Haffner et al.
20070276316 November 29, 2007 Haffner et al.
20070282244 December 6, 2007 Tu et al.
20070282245 December 6, 2007 Tu et al.
20070293807 December 20, 2007 Lynch et al.
20080015488 January 17, 2008 Tu et al.
20080027304 January 31, 2008 Pardo
20080045878 February 21, 2008 Bergheim et al.
20080058704 March 6, 2008 Hee et al.
20080108933 May 8, 2008 Yu
20080195027 August 14, 2008 Coroneo
20080200860 August 21, 2008 Tu et al.
20080228127 September 18, 2008 Burns et al.
20080234624 September 25, 2008 Bergheim et al.
20090036819 February 5, 2009 Tu et al.
20090043321 February 12, 2009 Conston et al.
20090138022 May 28, 2009 Tu et al.
20090182421 July 16, 2009 Silvestrini et al.
20100010416 January 14, 2010 Juan, Jr. et al.
20100134759 June 3, 2010 Silvestrini et al.
20100137981 June 3, 2010 Silvestrini et al.
20100152641 June 17, 2010 Yablonski
20100268232 October 21, 2010 Betz
20100274259 October 28, 2010 Yaron et al.
20110028883 February 3, 2011 Juan, Jr. et al.
20110028884 February 3, 2011 Theodore Coroneo
20110087149 April 14, 2011 Theodore Coroneo
20110087150 April 14, 2011 Theodore Coroneo
20110087151 April 14, 2011 Theodore Coroneo
20110098629 April 28, 2011 Juan, Jr. et al.
20110306915 December 15, 2011 De Juan, Jr. et al.
Foreign Patent Documents
1285724 February 2001 CN
0 228 185 November 1986 EP
1173124 January 2002 EP
1173125 January 2002 EP
1173126 January 2002 EP
1184010 March 2002 EP
1278492 January 2003 EP
1292256 March 2003 EP
1310222 May 2003 EP
1473004 November 2004 EP
1477146 November 2004 EP
1651291 May 2006 EP
1418868 March 2008 EP
1977724 October 2008 EP
1545655 December 2008 EP
2027837 February 2009 EP
2101891 January 1983 GB
2007-535386 December 2007 JP
2018289 August 1994 RU
2056818 March 1996 RU
2074686 March 1997 RU
2074687 March 1997 RU
2157678 October 2000 RU
WO-89/00869 February 1989 WO
WO-91/12046 August 1991 WO
WO-92/19294 November 1992 WO
WO-94/02081 February 1994 WO
WO-94/09721 May 1994 WO
WO-94/09837 May 1994 WO
WO-94/13234 June 1994 WO
WO-96/20742 July 1996 WO
WO-98/23237 June 1998 WO
WO-98/30181 July 1998 WO
WO-99/26567 June 1999 WO
WO-00/06223 February 2000 WO
WO-00/64389 November 2000 WO
WO-00/64390 November 2000 WO
WO-00/64391 November 2000 WO
WO-00/64393 November 2000 WO
WO-00/64511 November 2000 WO
WO-01/078631 October 2001 WO
WO-01/78656 October 2001 WO
WO-01/097727 December 2001 WO
WO-02/036052 May 2002 WO
WO-02/070045 September 2002 WO
WO-02/074052 September 2002 WO
WO-02/080811 October 2002 WO
WO-02/080829 October 2002 WO
WO-02/087418 November 2002 WO
WO-02/087479 November 2002 WO
WO-02/089699 November 2002 WO
WO-02/102274 December 2002 WO
WO-03/015659 February 2003 WO
WO-03/015667 February 2003 WO
WO-03/041622 May 2003 WO
WO-03/073968 September 2003 WO
WO-03/096871 November 2003 WO
WO-03/099175 December 2003 WO
WO-2004/014218 February 2004 WO
WO-2004/026347 April 2004 WO
WO-2004/043231 May 2004 WO
WO-2004/056294 July 2004 WO
WO-2004/060219 July 2004 WO
WO-2004/062469 July 2004 WO
WO-2004/073552 September 2004 WO
WO-2004/110391 December 2004 WO
WO-2005/016418 February 2005 WO
WO-2005/046782 May 2005 WO
WO-2005/055873 June 2005 WO
WO-2005/105197 November 2005 WO
WO-2005/107664 November 2005 WO
WO-2005/107845 November 2005 WO
WO-2006/012421 February 2006 WO
WO-2006/036715 April 2006 WO
WO-2007/087061 August 2007 WO
WO-2007/115259 October 2007 WO
WO-2007/130393 November 2007 WO
WO-2008/061043 May 2008 WO
WO-2009/012406 January 2009 WO
WO-2009/158517 December 2009 WO
WO-2009/158524 December 2009 WO
Other references
  • Barsky et al. “Evaluation of absorbable gelatin film (Gelfilm) in cyclodialysis clefts” Arch. Ophth. 60(6): 1044-1052, 1958.
  • Bick MW “Use of tantalum for ocular drainage” Arch Ophthal. 42(4): 373-88 (1949).
  • Bietti “The present state of the use of plastics in eye surgery” Acta Ophthalmol (Copenh) 33(4):337-70 (1955).
  • Brown et al., “Internal Sclerectomy for Glaucoma Filtering Surgery with an Automated Trephine,” Archives of Ophthalmology, 105:133-136 (1987).
  • Burchfield JC, Kass MA, Wax MB. Primary valve malfunction of the Krupin eye valve with disk. J Glaucoma. Jun. 1997;6(3):152-6.
  • Chiou et al. “Ultrasound biomicroscopy of eyes undergoing deep sclerectomy with collagen implant” Br J Ophthalmol 80 (1996), pp. 541-544.
  • Chylack LT, Bellows AR. Molecular sieving in suprachoroidal fluid formation in man. Invest Ophthalmol Vis Sci 17: 420, 1978.
  • Classen et al. “A histopathologic and immunohistorchemical analysis of the filtration bleb after unsuccessful glaucoma seton implantation” Am. J. Ophthalmol. 122:205-12 (1996).
  • Cohen et al. “First day post-operative review following uncomplicated phacoemulsification” Eye 12(4):634-6 (1998).
  • Collaborative Normal-Tension Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
  • Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
  • Coote. “Glaucoma Hollow Fiber Filters—A New Glaucoma Seton. Preliminary Results.” J. Glaucoma. vol. 8 No. 1 Supplement (1999):p. S4.
  • Cullen, et al. “Anterior Chamber of Frontal Sinus Shunt for the Diversion of Aqueous Humor: A Pilot Study in Four Normal Dogs”. Veterinary Ophthalmology. vol. 1. No. 1. (1998):31-39.
  • Demailly et al. “Non-penetrating deep sclerectomy (NPDS) with or without collagen device (CD) in primary open-angle glaucoma: middle-term retrospective study” International Ophthalmology 20: 131-140, 1997.
  • Derwent English abstract for EP 1184010, published Mar. 6, 2002 entitled: “Drainage unit for an eye, consists of a hollow line, a distribution member, and a pressure relief valve which only allows water to leave the eye chamber above a certain pressure,” Accession Nbr. 12409716 [351].
  • Dinakaran et al. “Is the first post-operative day review necessary following uncomplicated phacoemulsification surgery?” Eye, 14(3A):364-6 (2000).
  • Draeger “Chirurgische Maβnahmen bei kongenitalem Glaukom” (Surgical Interventions in Congenital Glaucoma) Klin Monatsbl Augenheilkd 1993; 202(5): 425-427 [Article in German with English summary included].
  • Einmahl et al. “Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye” Invest Ophthalmol Vis Sci. 43:1533-1539 (2002).
  • Ellis, RA “A Reduction of Intraocular Pressure Using Plastics in Surgery” Am J Ophth. 50; 1960, 733-742.
  • Emi et al. “Hydrostatic pressure of the suprachoroidal space” Invest. Ophthal. Visual Sci. 30(2):233-238 (1989).
  • Fanous MM, Cohn RA. Propionibacterium endophthalmitis following Molteno tube repositioning. J Glaucoma. Aug. 1997;6(4):201-2.
  • Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8.
  • Fuchs E. “Detachment of the choroid inadvertently during cataract surgery” [German] von Graefes Arch Ophthalmol, 51:199-224 (1900) [Article in German with English summary].
  • G. Van Der Veen et al. “The Gonioseton, a surgical treatment for chronic glaucoma” Documenta Ophthalmologica Oct. 1990, vol. 75, Issue 3-4, pp. 365-375.
  • Gills et al. “Action of cyclodialysis utilizing an implant studied by manometry in a human eye” Exp Eye Res 1967; 6:75-78.
  • Gills JP “Cyclodialysis implants” South Med J. 1967 60(7):692-5.
  • Gills, “Cyclodialysis Implants in Human Eyes” Am J Ophth 61:1966,841-846.
  • Goldberg “Management of Uncontrolled Glaucoma With the Molteno System” Australian and New Zealand Journal of Ophthalmology 1987; 15: 97-107.
  • Gordon MO, Kass. MA, for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Design and baseline description of the participants. Arch Ophthalmol 1999:573-83.
  • Grant, W.M. , MD, Further Studies on Facility of Flow Through the Trabecular Meshwork, A.M.A. Archives of Ophthalmololgy, Oct. 1958, vol. 60, pp. 523-533.
  • Gross et al. “Surgical therapy of chronic glaucoma in aphakia and pseudophakia” Ophthalmology, 95:1195-201 (1988).
  • Harper SL, Foster CS. Intraocular lens explantation in uveitis. Int Ophthalmol Clin. 2000 Winter; 40(1):107-16.
  • Harrington “Cataract and Glaucoma. Management of the coexistent conditions and a description of a new operation combining lens extraction with reverse cyclodialysis.” Am J Ophthalmol. May 1966;61(5 Pt 2):1134-40.
  • Heijl A, Leske MC, Bengtsson B, et al for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
  • Heine I. “Cyclodialysis, a new glaucoma operation” [German] Dtsch Med Wochenschr, 31:824-826 (1905).
  • Hildebrand et al. “Efficacy of anterior chamber decompression in controlling early intraocular pressure spikes after uneventful phacoemulsification” J. Catact Refract Surg., 29:1087-92 (2003).
  • Hoskins, et al., “Aqueous Humor Outflow”, Becker-Shaffer's Diagnosis and Therapy of the Glaucomas, 6th Edition, Chapter 4, pp. 41-66, 1989.
  • Howorth D J “Feasibility study for a micromachined glaucoma drainage device” Cranfield University School of industrial and manufacturing science MSc Thesis Academic Year 2001-2002 Sep. 13, 2002.
  • Hylton et al. “Update on prostaglandin analogs” Curr Opin Ophthalmol, 14:65-9 (2003).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”), Commonwealth of Australia—Opponent's Statement of Grounds and Particulars of Opposition. (Apr. 10, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Mr. Craig Andrews in support of Opponent's opposition. (Sep. 9, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Colin Clement in support of Opponent's opposition. (Sep. 9, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Ilesh Patel in support of Opponent's opposition. (Sep. 9, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Opponent's Amended Statement of Grounds and Particulars of Opposition. (Sep. 10, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Robert L. Stamper in support of Applicant's Evidence in Answer. (Dec. 4, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Jonathan G. Crowston in support of Applicant's Evidence in Answer. (Dec. 6, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Anne Jen-Wan Lee in support of Applicant's Evidence in Answer. (Dec. 7, 2014).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Colin Clement in support of Opponent's Evidence in Reply. (Feb. 8, 2015).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Dr. Ilesh Patel in support of Opponent's Evidence in Reply. (Feb. 10, 2015).
  • In the Commonwealth of Australia—In the Matter of Australian Patent Application No. 2006336598 in the name of Transcend Medical, Inc. (“Applicant”) and Opposition thereto by Glaukos Corporation (“Opponent”)—Declaration of Mr. Craig Andrews in support of Opponent's Evidence in Reply. (Feb. 11, 2015).
  • Javitt JC, Chiang YP. Preparing for managed competition. Utilization of ambulatory eye care visits to ophthalmologists. Arch Ophthalmol 1993;111:1034-5.
  • Jay JL, Allan D. The benefit of early trabeculectomy versus conventional management in primary open-angle glaucoma relative to severity of disease. Eye 1989; 3:528-35.
  • Jordan J. “A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma” J. Glaucoma 15:200-205 (2006).
  • Karlen et al. “Deep sclerectomy with collagen implant: medium term results” Br. J. Ophthalmol, Jan. 1999, 83(1):6-11.
  • Kass MA, Heuer DK, Higginbotham EJ, et al for the Ocular Hypertension Treatment Study Group. The Ocular HypertensionTreatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
  • Klemm et al. “Die Ultraschallbiomikroskopie als Kriterium der Funktionsprüfung des suprachorioidalen Spaltes nach kammerwinkelchirurgischen Eingriffen ; (Ultrasound Biomicroscopic Imaging for Assessment of the Suprachoroidal Cleft after Angle Surgery)” Klinische Monatsblätter für Augenheilkunde 1997; 210: 74-77 [Article in German with English summary included].
  • Klemm et al. “Experimental use of space-retaining substances with extended duration: functional and morphological results” Graefes Arch Clin Exp Ophthalmol Sep. 1995; 233(9):592-7.
  • Krejci “Cyclodialysis with hydroxymethyl methacrylate capillary strip (HCS). Animal experiments with a new approach in glaucoma drainage surgery” Ophthalmologica 1972; 164(2):113-21.
  • Krejci L. “Microdrainage of anterior chamber of eye glaucoma operation using hydron capillary drain.” Acta Univ Carol Med Monogr. 1974;(61):1-90.
  • Kupfer “Studies on intraocular pressure. I. A technique for polyethylene tube implantation into the anterior chamber of the rabbit.” Arch Ophthalmol. Apr. 1961;65:565-70.
  • La Rocca “Gonioplasty in Glaucoma*A Preliminary Report” Br J Ophth 46:1962, 404-415.
  • Law et al., “Retinal Complications After Aqueous Shunt Surgical Procedures for Glaucoma” Arch Ophthal.; Dec. 1996; vol. 114:1473-1480.
  • Lee et al. “Aqueous-venous shunt and intraocular pressure. Preliminary report of animal studies.” Investigative Ophthalmology. vol. 5 No. 1: 59-64. Feb. 1966.
  • Lee et al. “Magnetic resonance imaging of the aqueous flow in eyes implanted with the trabeculo-suprachoroidal glaucoma seton” Invest. Ophthalmol. Vis. Sci. 33:948 (1992).
  • Lee KY. Trabeculo-suprachoroidal shunt for treating recalcitrant and secondary glaucoma. Presented at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, 1991.
  • Leske MC, Heijl A, Hussein M, et al for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. The Early Manifest Glaucoma Trial. Arch Ophthalmol Jan. 2003;121:48-56.
  • Lichter PR, Musch DC, Gillespie BW, et al and the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
  • Losche W. “Proposals for improvement of cyclodialysis” Klin Monatsblatter Augenheilkd Augenarztl Fortbild 121(6):715-6 (1952) [German].
  • Marx et al., “Use of the Ganciclovir Implant in the Treatment of Recurrent Cytomegalovirus Retinitis” Arch Ophthal.; Jul. 1996; vol. 114:815-820.
  • McPherson “Combined Trabeculotomy and Cataract Extraction as a Single Operation*” Tr. Am. Ophth. Soc., vol. LXXIV, 1976; 251-260.
  • Migdal C, Gregory W, Hitchings R. Long term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-7.
  • Miglior S, Pfeiffer N, Zeyen T et al for the European Glaucoma Prevention Study Group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75.
  • Miglior S, Zeyen T, Pfeiffer N, et al for the European Glaucoma Prevention Study Group. The European Glaucoma Prevention Study design and baseline description of the participants. Ophthalmology 2002;109:1612-21.
  • Miki, MD et al., “Intraocular Cannula for Continuous, Chronic Drug Delivery—Histopathic Observations and Function” Arch Ophthal.; May 1985; vol. 103:712-717.
  • Molteno et al. “Long tube implants in the management of glaucoma” South African Medical Journal, Jun. 26, 1976;50(27):1062-6.
  • Molteno et al. “The Vicryl tie technique for inserting a draining implant in the treatment of secondary glaucoma.” Australian and New Zealand Journal of Ophthalmology 1986; 14: 343-354.
  • Moses RA “Detachment of ciliary body-anatomical and physical considerations” Investigative Ophthalmology & Visual Science, Assoc. for Research in Vision and Ophthalmology, US, vol. 4, No. 5, Oct. 1, 1965.
  • Nesterov AP et al. “Surgical stimulation of the uveoscleral outflow. Experimental studies on enucleated human eyes” Acta Opthalmol (Copenh) June; 57(3):409-17 (1979).
  • Nguyen et al., “Complications of Baerveldt Glaucoma Drainage Implants” Arch Ophthal.; May 1998; vol. 116:571-575.
  • Noecker RJ. Clinical Evaluation of a Novel Gold Micro-Shunt for Reduction of 10 P in Refractory Glaucomas. American Glaucoma Society Annual Meeting, San Francisco, CA, 2007.http://www.glaucomaweb.org/associations/5224/files/AGS%20AM07%20Prgrm%20FINAL.pdf. Accessed Nov. 1, 2008).
  • O'Brien et al. “Cyclodialysis” Arch Ophthal. 1949;42(5):606-619.
  • Odrich. “The New Technique During Complex Tube-Shunt Implantation”. J. Glaucoma. vol. 9 No. 3 (2000):278-279.
  • Olsen, Timothy W., et al., Cannulation of the Suprachoroidal Space: A Novel Drug Delivery Methodology to the Posterior Segment, American Journal of Ophthalmology, vol. 142, No. 5, Nov. 2006, pp. 777-787.e2.
  • Ozdamar et al. “Suprachoroidal seton implantation in refractory glaucoma: a novel surgical technique” J. Glaucoma Aug. 2003; 12(4):354-9.
  • Pinnas G. et al. “Cyclodialysis with teflon tube implants” Am J. Ophthalmol Nov. 1969; 68(5):879-883.
  • Portney GL, “Silicone elastomer implantation cyclodialysis.” Arch Ophthalmol 1973; 89: 10-12.
  • Pruett et al., “The Fishmouth Phenomenon-II. Wedge Scleral Buckling” Arch Ophthal.; Oct. 1977; vol. 95:1782-1787.
  • Qadeer “Acrylic Gonio-Subconjunctival Plates in Glaucoma Surgery” Br J Ophthalmol. Jun. 1954; 38(6): 353-356.
  • Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38:83-91.
  • Richards et al. “Artificial Drainage Tubes for Glaucoma” Am J Ophth 60:1965,405-408.
  • Ritch, et al., “Uveoscleral Outflow”, The Glaucomas. St. Louis: Mosby, 1996; pp. 337-343.
  • Rohen, Johannes W., Anatomy of the Aqueous Outflow Channels, Glaucoma, vol. 1, Chapter 14, pp. 277-296, Edited by J.E. Cairns, Grune & Stratton, Harcourt Brace Jovanovich Publishers, 1986.
  • Rosenberg, et al. “Implants in glaucoma surgery” Chapter 88, The Glaucomas, Ritch et al. Eds. 2nd Ed. Mosby St. Louis 1996; p. 1783-1807.
  • Row H. “Operation to control glaucoma: preliminary report” Arch. Ophthal 12:325 (1934).
  • Rowan, Patrick J., MD, Combined Cyclodialysis and Cataract Surgery, Ophthalmic Surgery and Lasers, Dec. 1998, vol. 29, No. 12, pp. 962-968 (9 pages).
  • Sampimon “A New Approach to Filtering Glaucoma Surgery” Ophthalmologica (Basel) 151: 1966, 637-644.
  • Schappert S. Office visits for glaucoma: United States, 1991-92. Advance data from vital and health statistics. vol. 262. Hyattsville, MD: National Center for Health Statistics, 1995.
  • Schocket, Stanley S. “Investigations of the Reasons for Success and Failure in the Anterior Shunt-To-The-Encircling-Band Procedure in the Treatment of Refractory Glaucoma.” Tr. Am. Ophth. Soc. vol. LXXXIX. (1986):743-798.
  • Shaffer RN, Weiss DI. Concerning cyclodialysis and hypotony. Arch Ophthalmol 68: 25, 1962.
  • SOLX Clinical Literature Handout; Industry Show Feb. 2006; “The SOLX Gold Micro-shunt (GMS) treatment”.
  • Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991;325:1412-7.
  • Sourdille et al. “Reticulated hyaluronic acid implant in non-perforating trabecular surgery.” J Cataract Refract Surg 25: 332-339. (1999).
  • Spiegel et al. “Schlemm's Canal Implant: A New Method to Lower Intraocular Pressure in Patients With POAG?” Ophthalmic Surgery and Lasers. vol. 30, No. 6: 492-494. Jun. 1999.
  • Srinivasan et al. “Microbial contamination of the anterior chamber during phacoemulsification” J. Cataract Refract Surg. 28:2173-6 (2002).
  • Suguro K, Toris CB, Pederson JE. Uveoscleral outflow following cyclodialysis in the monkey eye using a fluorescent tracer. Invest Ophthalmol Vis Sci 1985: 26, 810.
  • The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
  • The Advanced Glaucoma Intervention Study (AGIS); 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111:651-64.
  • The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results. Am J Ophthahnol 1995;120:718-31.
  • The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology 1990;97:1403-13.
  • Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74.
  • Toris CB. Extravascular albumin concentration of the uvea. Invest Ophthalmol Vis Sci 1990; 31:43.
  • Toris et al. “Aqueous humor dynamics in the aging human eye” Am J. Ophthalmol., 127:407-12 (1999).
  • Toris et al. “Effect of intraocular pressure on uveoscleral outflow following cyclodialysis in the monkey eye.” Investigative Ophthalmology & Visual Science. 26 (1985) 1745-1749.
  • Transcend Medical Inc. v. Glaukos Corporation, Transcend Medical, Inc.'s Disclosures Pursuant to Default Discovery Rule 4 (d) (United States District Court for the District of Delaware, dated Dec. 6, 2013; case No. C.A. No. 13-830 (MSG) and Certificate of Service, dated Dec. 9, 2013.
  • Trigler L, Proia AD, Freedman SF. Fibrovascular ingrowth as a cause of Ahmed glaucoma valve failure in children. Am J Ophthalmol. Feb. 2006;141(2):388-9.
  • Troncoso Manuel U., “Cyclodialysis with insertion of metal implant in treatment of glaucoma, A Preliminary Report” Arch. Ophthal. 23:270 (1940).
  • Troncoso, Manuel U., Tantalum implants for inducing hypotny, Am Journal of Ophthalmology, vol. 32(4):499-508 (1949).
  • Wagner, Justin A., et al., Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused under Constant Pressure, Invest Ophthalmol Vis Sci., Published in edited form in Sep. 2004, vol. 45, Issue 9, pp. 3203-3206.
  • Wamsley S, Moster MR, Rai S, Alvim HS, Fontanarosa J. Results of the use of the Ex-PRESS miniature glaucoma implant in technically challenging, advanced glaucoma cases: a clinical pilot study. Am J Ophthalmol. Dec. 2004; 138(6): 1049-51.
  • Yablonski, “Some thoughts on the pressure dependence of uveoscleral flow” Journal of Glaucoma, 12(1):90-92 (2003).
  • Yablonski, “Trabeculectomy with Internal Tube Shunt: a novel glaucoma surgery” J. Glaucoma 14:91-97 (2005).
  • Zhou et al. “A trabecular bypass flow hypothesis” J Glaucoma. 14(1):74-83 (2005).
Patent History
Patent number: 9987163
Type: Grant
Filed: Apr 16, 2014
Date of Patent: Jun 5, 2018
Patent Publication Number: 20140309599
Assignee: Novartis AG (Basel)
Inventor: Michael Schaller (Menlo Park, CA)
Primary Examiner: Todd J Scherbel
Assistant Examiner: Sara Sass
Application Number: 14/254,366
Classifications
Current U.S. Class: Having A Fluid Filled Chamber (623/17.12)
International Classification: A61F 9/00 (20060101); A61M 5/315 (20060101); A61M 5/24 (20060101); A61M 5/31 (20060101);